問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Far Eastern Memorial Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間：2023-09-19

鄭世隆
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

28Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭世隆

Far Eastern Memorial Hospital

Division of Thoracic Medicine

List

45Cases

2021-03-01 - 2026-07-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-05-31 - 2027-05-30

Phase II

Active
A randomized, double-blind, placebo-controlled, parallel- group, Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab, in participants with non-cystic fibrosis bronchiectasis

  • Condition/Disease

    non-cystic fibrosis bronchiectasis

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting5Sites

2022-07-01 - 2030-01-22

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-06-01 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-02-01 - 2029-12-31

Phase III

Active
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of NCT05211895

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Durvalumab Domvanalimab

Participate Sites
9Sites

Recruiting9Sites

2009-07-01 - 2010-07-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2014-06-01 - 2015-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-05-30 - 2013-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2022-01-31 - 2024-12-10

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-09-01 - 2025-02-14

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB